Monday - Friday: 8 AM to 4.30PM
P: 08 8944 8220
F: 08 8944 8222
NTROADMIN.DoH@nt.gov.au

Clinical Trials

The Radiation Oncology, Medical Oncology and Haematology at the Alan Walker Cancer Care Centre, Royal Darwin Hospital jointly conducts research and clinical trials to find more effective ways to prevent, treat, cure and support those living with cancer. Our clinical trials also provide the opportunities for our patients to access leading edge treatment and care protocols.

Alan Walker Cancer Care Centre promotes integrity in its research and clinical trials as it operates in accordance with the National Health and Medical Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research (2007).

TROG – ‘STARS’ Breast Cancer 

A randomised comparison of Anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy

RADIOTHERAPY TALKING BOOK

A radiotherapy audiobook in simple English and Yolgnu Matha language

MOST

The Cancer Molecular Screening & Therapeutics (MoST) Program-A Framework protocol for multiple, parallel, signal-seeking clinical studies of molecularly targeted therapies for patients with advanced cancer and unmet needs.

ASCOLT

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers – An International, Multi-centre, Double Blind, Randomised Placebo Controlled Phase III Trial.

ENZAMET

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer

SUPER CUP 

A prospective cohort study of patients with Cancer of Unknown Primary (CUP) to create a national information resource and improve the understanding of the molecular biology, clinical, quality of life and psychosocial characteristics

KEYNOTE

MK3475-689 (MSD) A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in combination with Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Loco regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NAVIGATE

A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors (lung, non-secretory breast, melanoma and colorectal cancers).

INTEGRATE IIb

A Randomised Phase III Controlled Trials of Regorafenib containing regimens versus standard of care in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

DYNAMIC III

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in stage III Colon Cancer: A Multicentre Phase II/III randomised Controlled study.

SUPER NEXT

Peter Mac – Complete Whole Genome Sequencing for Cancer of Unknown Primary

BCT 1901: CAPTURE

Phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced Breast Cancer patients with PIK3CA mutant circulating DNA. The study includes a number of translational research objectives.

AMLM22

Multi-arm study platform to compare the efficacy of experimental therapies with standard of care in patients with AML in first complete remission. It incorporates testing of multiple experimental drugs in a simultaneous and perpetual manner. 

FRAIL-M study MM22

Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma – the FRAIL-M study

VALDAC

A phase 2 study of Venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukaemia